Human very low density lipoprotein receptor,VLDLR ELISA Kit

Code CSB-E08951h
Size 96T,5×96T,10×96T How to order?
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details


This Human VLDLR ELISA Kit was designed for the quantitative measurement of Human VLDLR protein in serum, plasma. It is a Sandwich ELISA kit, its detection range is 1.25 ng/mL-80 ng/mL and the sensitivity is 0.31 ng/mL.

Target Name very low density lipoprotein receptor
Alternative Names FLJ35024 ELISA Kit; Very low density lipoprotein receptor ELISA Kit; Very low-density lipoprotein receptor ELISA Kit; VLDL R ELISA Kit; VLDL receptor ELISA Kit; VLDL-R ELISA Kit; VLDLR ELISA Kit; VLDLR_HUMAN ELISA Kit; VLDLRCH ELISA Kit
Abbreviation VLDLR
Uniprot No. P98155
Species Homo sapiens (Human)
Sample Types serum, plasma
Detection Range 1.25 ng/mL-80 ng/mL
Sensitivity 0.31 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Metabolism
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human VLDLR in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %91
Range %86-95
1:2Average %102
Range %97-107
1:4Average %91
Range %85-97
1:8Average %97
Range %91-103
The recovery of human VLDLR spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9589-98
EDTA plasma (n=4)9790-100
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
802.612 2.699 2.656 2.484
402.173 2.107 2.140 1.968
201.428 1.438 1.433 1.261
100.898 0.842 0.870 0.698
50.546 0.569 0.558 0.386
2.50.393 0.389 0.391 0.219
1.250.275 0.279 0.277 0.105
00.171 0.173 0.172
ELISA Data Analysis Watch ELISA data processing video & download Curve Expert if needed
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation.
Gene References into Functions
  1. In summary, ER retention of pathogenic VLDLR mutants involves binding to calnexin, elevated endoplasmic reticulum stress, and delayed degradation which is dependent on SEL1L. PMID: 29371607
  2. Our findings described an atherogenic phenotype characterized by low VLDL-C but high VLDLR mRNA expression in peripheral WBCs, which suggested that VLDLR in all types of peripheral WBCs may be involved in lipid deposition, and VLDL-C and VLDLR may co-determine the development of atherosclerosis. PMID: 29042132
  3. In the second family, we identified a previously unreported homozygous missense change, c.154T > C (p.Cys52Arg) in the VLDLR gene PMID: 27108886
  4. VLDLR expression was negatively regulated by miR-200c Colorectal cancer (CRC) cells and their expression levels were inversely correlated in CRC patients. PMID: 28112443
  5. We screened for mutations in RELN or VLDLR and compared the phenotype of these patients with that of previously reported patients. differences in clinical severity, involvement of the cerebellar hemispheres, together with the severity of the neocortical defect, enables RELN-mutated patients to be distinguished from VLDLR-mutated patients. PMID: 27000652
  6. Data suggest that, in the binding of fibrin beta N-domains and the (1-8) peptide fragment of VLDLR (very low density lipoprotein receptor), the second and third Lys/Arg clusters in fibrin make major contributions to this interaction while the contribution of the first cluster is moderate. PMID: 28437098
  7. The presence of reelin was elevated in junctional areas as in dysplastic nevi. VLDLR presented positive values in 16 cases (16/ 32) and ApoER2 was weak positive in 7 cases. PMID: 28255385
  8. These results for the first time demonstrated that SalA protected against IS/RP-induced endothelial barrier dysfunction through suppression of VLDL receptor expression PMID: 24662412
  9. these results suggest that VLDLR functions in vivo as an HCV receptor independent of canonical CD81-mediated HCV entry. PMID: 26699506
  10. the results obtained indicate that minimal fibrin-binding structures are located within the second and third CR domains of the VLDL receptor and the presence of the fourth CR domain is required for high-affinity binding PMID: 26153297
  11. The results of this study demonstrated the presence of reelin, its receptors VLDLR and ApoER2 as well as Dab1 in the ENS and might indicate a novel role of the reelin system in regulating neuronal plasticity and pre-synaptic functions in the ENS. PMID: 24844606
  12. these results suggested that the miR-135a-VLDLR-p38 axis may contribute to gallbladder cancer cell proliferation PMID: 24903309
  13. study identified a novel homozygous VLDLR c.2248C>T mutation (p.Q750X) and distinctive MRI findings in 2 siblings with ataxia; also marked vitamin E deficiency was detected in the proband PMID: 23813796
  14. these results identify a novel role for the VLDLR as a negative regulator of DC-mediated adaptive immune responses in HDM-induced allergic airway inflammation. PMID: 24733846
  15. ectopic expression of HIC1 in U2OS and MDA-MB-231 cell lines decreases expression of the ApoER2 and VLDLR genes, encoding two canonical tyrosine kinase receptors for Reelin. PMID: 24076391
  16. an unusual constellation of VLDLR mutations in Cerebellar ataxia, mental retardation and dysequilibrium syndrome 1 is reported PMID: 23670308
  17. Results show variation in VLDLR is implicated in disordered gambling PMID: 22780124
  18. These results conclude that in the hypoxic hearts of mice and men, the VLDLr gene is regulated by a direct binding of Hif-1alpha to the VLDLr promoter PMID: 23811271
  19. Stx5 might play a role in modulating VLDL-R physiology by participating in an abrasively described or completely novel Golgi-bypass pathway. PMID: 23701949
  20. In this report, we present 3 patients from 2 different families displaying very low density lipoprotein receptor-associated pontocerebellar hypoplasia, cortical dysplasia, mental retardation, and bipedal gait. PMID: 22532556
  21. The pathological increase of HIF-1alpha in clear-cell renal cell carcinoma cells upregulates VLDL-R, which mediates increased uptake and accumulation of lipids. PMID: 23185271
  22. Insulin could down-regulate expression of type I VLDLR and up-regulate the expression of type II VLDLR in SGC7901 cells. PMID: 21063833
  23. A homozygous missense mutation (c.2117 G > T, p.C706F) is identified in the VLDLR gene in both families on a shared affected haplotype block. PMID: 22973972
  24. Variation in genes encoding proteins at the gateway of Reelin signaling: ligands RELN and APOE, their common receptors APOER2 and VLDLR, and adaptor DAB1, was examined. PMID: 22419519
  25. VLDLR encodes very low-dentisy lipoprotein receptor. PMID: 22876580
  26. In the expression study, only ARG1 (4.5-fold) and VLDLR (4-fold) expressions were significantly upregulated in the overweight group compared with the normal-weight group. PMID: 22189190
  27. Copy number variation of VLDLR is associated with age-related macular degeneration. PMID: 22355348
  28. In later stages of cerebral cortical development, ApoER2 is expressed earlier than VLDLR in migrating neurons. PMID: 21601501
  29. activation of VLDLR and apoER2 by reelin and apoE induces ABCA1 expression and cholesterol efflux via a Dab1-PI3K-PKCzeta-Sp1 signaling cascade. PMID: 22170052
  30. RIG-I signaling results in the inhibitions of infections of rhinoviruses 1B through the miR-23b-mediated down-regulation of its receptor VLDLR PMID: 21642441
  31. VLDLR II may have a role in lymph node and distant metastasis in gastric and breast cancer patients, and has a potential link with beta-catenin signaling pathway PMID: 21047397
  32. VLDL or beta-VLDL-induced VLDLR expression via PKC/ERK cascades and the effect was linked to the transcriptional activation of VLDLR gene promoter. PMID: 19224153
  33. These results indicated that extracellular ligands can change the expression of type II VLDLR to affect cell proliferation and migration. PMID: 20624392
  34. Transfected ecombinant human VLDLR bound mouse Pafah1b3 or Pafah1b2 but not with Lis1. PMID: 17330141
  35. binds to two adjacent copies of human rhinovirus VP1 proteins PMID: 12857919
  36. like the LDL receptor, LRP prefers lipid-bound forms of apoE, but in contrast to the LDL receptor, both LRP and the VLDL receptor recognize all apoE isoforms PMID: 15863833
  37. The effects of apoE on receptor proteolysis were mediated by the ligand binding domain of the receptor. We suggest that signaling promoted by these receptors depends in part on these regulated proteolytic events. PMID: 15950758
  38. These artificial receptors protected HeLa cells against infection with human rhinovirus serotype 2 (HRV2) to a degree that strongly increased with the number of repeats present. PMID: 15950998
  39. Results suggest that VLDLR CGG repeat polymorphism was associated with bone mineral density (BMD) in men, with two (CGG)(n > or= 8) alleles being related to increased BMD. PMID: 15953542
  40. Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification. PMID: 16080122
  41. fluorescence correlation spectroscopy was used to determine the equilibrium binding constants and the mode of attachment of recombinant concatemers of ligand binding module 3 of the human VLDLR to Human rhinovirus HRV2 PMID: 17472347
  42. VLDLR functions as a negative regulator of CNV, and this function is mediated through the wnt pathway. PMID: 17890782
  43. Our findings suggest that peripheral VLDLR mRNA levels may serve as a reliable peripheral biological marker of schizophrenia, and that the reelin-VLDLR/ApoER2 signaling pathway plays a role in the pathophysiology of schizophrenia. PMID: 17936586
  44. TSP1 and TSP2, together with the VLDLR, initiate a nonapoptotic pathway for maintenance of the normal adult vascular endothelium in a quiescent state. PMID: 18032585
  45. the activity of PCSK9 and its binding affinity on VLDLR and ApoER2 does not depend on the presence of LDLR. PMID: 18039658
  46. A nonsense mutation in patients with dysequilibrium syndrome affects the very low-density lipoprotein receptor (VLDLR) exclusively, confirming the central role of the VLDLR in the etiology of this condition. PMID: 18043714
  47. one tagSNP (SNP 1226; rs1454626) located in the 5' flanking region of VLDLR was associated with CAAD, BMI, and LDL-associated apoB. PMID: 18056683
  48. the binding sites for VLDLR (very low density lipoprotein receptor) and LRP (low-density lipoprotein receptor-related protein) within Factor VIII overlap and the A2 site becomes exposed upon physiological activation of Factor VIII. PMID: 18277139
  49. mutations in VLDLR impair cerebrocerebellar function, conferring in these families a dramatic influence on gait, and that hereditary disorders associated with quadrupedal gait in humans are genetically heterogeneous PMID: 18326629
  50. Associated with cerebellar ataxia, which can lead to quadrupedal locomotion. PMID: 18364738

Show More

Hide All

Involvement in disease Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 1 (CAMRQ1)
Subcellular Location Membrane; Single-pass type I membrane protein. Membrane, clathrin-coated pit; Single-pass type I membrane protein.
Tissue Specificity Abundant in heart and skeletal muscle; also ovary and kidney; not in liver.
Database Links

HGNC: 12698

OMIM: 192977

KEGG: hsa:7436

STRING: 9606.ENSP00000371532

UniGene: Hs.370422

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1